TL;DR
- 1.No baseline labs means no safety net. Any clinic that does not require pre-treatment blood work is not running a legitimate standard of care.
- 2.BPC-157 has exactly one human clinical study out of 36 total reviewed. Your lab monitoring is not a formality. It is the only real-time safety data being generated.
- 3.Your compounding pharmacy matters as much as your clinic. A 503B outsourcing facility with a third-party certificate of analysis is the minimum bar.
- 4.IGF-1 is the deciding marker for GH peptides. Target the 60th to 80th percentile of the age-adjusted range, not the ceiling.
- 5.Your existing 23andMe or AncestryDNA file contains the variant calls that predict which peptides will work best for your biology. Run the analysis before your appointment, not after.
Most people searching "peptide therapy near me" book the first clinic they find, show up without blood work, and walk out with a $250/month prescription they have no way to evaluate. Eight weeks later they do not know if anything worked because they had no baseline to compare against.
That is not a failure of peptides. It is a failure of preparation. The 7 steps below take about 10 days to complete before your first appointment. They are the difference between a measurable protocol and a blind experiment at your own expense.
Number of human clinical studies found for BPC-157 in a 2025 systematic review of 36 total published studies, published in HSS Journal (the journal of New York's Hospital for Special Surgery). Almost all existing BPC-157 data comes from animal models. Your lab work is not bureaucratic overhead. It is the only real-time safety data you will generate.
Think of your baseline labs as the "before" photo in a transformation. Without them you cannot prove the transformation happened, you cannot catch a problem early, and you have no data to bring back if something feels off. The full panel costs $100 to $200 at walk-in testing services. Skipping it to save money is roughly like removing the brakes from your car to make it lighter.
What to do before your first peptide therapy appointment (in order)
1. Order your baseline labs before you call the clinic
The standard pre-treatment panel for any peptide protocol includes a Comprehensive Metabolic Panel (CMP), a Complete Blood Count (CBC), a fasting lipid panel, HbA1c, fasting insulin, and a hormone panel with morning cortisol, total and free testosterone, and estradiol. The CMP covers your liver enzymes (ALT, AST, ALP), kidney markers (BUN, creatinine, eGFR), and fasting glucose. That baseline is how you know, later, whether the protocol is working or quietly causing harm.
For GH-releasing peptides specifically (sermorelin, ipamorelin, CJC-1295), add IGF-1 to the panel. For GLP-1-type peptides, add calcitonin and TSH. For healing and tissue-repair peptides like BPC-157 and TB-500, add high-sensitivity CRP and ESR as inflammatory baselines.
The red flag is simple: any clinic that does not require pre-treatment blood work is not running a legitimate standard of care. Walk-in lab services (Any Lab Test Now, LabCorp Direct, Quest Direct) let you order these without a doctor's order. The full panel runs $100 to $250. Order it before your first appointment, not after.
2. Learn what "almost no human data" actually means for you
A 2025 systematic review by Vasireddi and colleagues, published in HSS Journal: The Musculoskeletal Journal of Hospital for Special Surgery, reviewed 36 published studies on BPC-157. They found one human clinical study. The other 35 were animal models, nearly all in rats and mice.
Despite growing popularity, the evidence base for BPC-157 in humans remains extremely limited. Only one human clinical study was identified among the 36 studies reviewed. The absence of robust human trial data precludes definitive conclusions about efficacy and safety in clinical populations.
Vasireddi et al., HSS Journal: The Musculoskeletal Journal of Hospital for Special Surgery, 2025
This is not an argument against peptides. The animal data for BPC-157 is remarkably consistent. But it means one specific thing for how you approach safety: the lab monitoring you set up in step 1 is the only real-time human safety data available. No published RCT has established the liver enzyme threshold at which you should stop a BPC-157 protocol. You are setting those benchmarks yourself. That is exactly why skipping the baseline is not a minor inconvenience. It removes the entire safety net.
For what the animal data actually shows on healing outcomes, including why genetic variation explains so much of the response variance, the BPC-157 tendon healing and non-responder guide covers the research in detail.
3. Verify your compounding pharmacy before you commit to a clinic
The peptide your clinic prescribes is only as good as the pharmacy that produces it. A legitimate compounding pharmacy for peptides is either an FDA-registered 503B outsourcing facility or a 503A patient-specific compounder using verified USP-grade bulk drug substances. The difference is meaningful: 503B facilities operate under pharmaceutical cGMP standards with validated processes and documented quality control. Some peptide products tested in 2024 by independent laboratories contained as little as 62 percent of the labeled active compound alongside bacterial endotoxin contamination. That batch came from an unlicensed source.
Before you fill any prescription, ask your clinic two questions: "Which outsourcing facility do you source from?" and "Can I see the certificate of analysis for this batch?" A legitimate clinic will answer both immediately. If they redirect or say the COA is proprietary, find a different provider. You can verify 503B registration directly through the FDA's publicly searchable list of registered outsourcing facilities.
4. Check the legal status of the specific peptide being prescribed
The FDA's 2023 restrictions placed BPC-157, TB-500, and several other peptides on the Category 2 bulk drug substance list, which banned their preparation by licensed US compounding pharmacies. In April 2026, several were removed from that ban list. But removed from the ban list is not the same as legal to compound. The final gateway, Category 1 placement, requires a separate PCAC hearing currently scheduled for July 23-24, 2026.
Before paying a deposit or signing a subscription, ask your clinic directly: "Is this peptide currently on the FDA's approved 503A or 503B bulk substances list?" A legitimate provider will know the answer and cite the specific document. Ipamorelin and CJC-1295 received negative PCAC votes in late 2024 and are not part of the July 2026 review. Any clinic actively prescribing those compounds is operating outside the regulatory framework. The 2026 US peptides legal guide covers every major peptide's current status with specific citations to the FDA documents and PCAC vote records.
IGF-1 is the single number that tells you if GH peptides are working
5. Know your IGF-1 before starting any GH-releasing peptide
If your protocol includes any growth hormone-releasing peptide, sermorelin, CJC-1295, ipamorelin, or tesamorelin, your pre-treatment IGF-1 is the most important number in your chart. IGF-1 is the downstream liver signal produced in response to GH output. It has a stable enough half-life to measure reliably from a standard blood draw, unlike GH itself which spikes and crashes through the day.
A 2024 study in Acta Biochimica et Biophysica Sinica by Liu and colleagues at the Chinese Academy of Sciences and Shanghai Jiao Tong University found that baseline IGF-1 and BMI together predicted GH peptide therapy response with a correlation coefficient of 0.957. The study also identified 38 predictive SNPs across 18 genes, particularly HSD3B1 and INSR in the IGF-1 pathway, as significant response predictors. Your starting IGF-1 is not just a safety marker. It is one of the strongest predictors of how much benefit you will get from any GH protocol.
Target IGF-1 percentile for the age-adjusted reference range during a GH peptide protocol. Evidence-informed practitioners target this window, not the absolute ceiling. Above the 95th percentile for your age, the risk-benefit calculation shifts materially. Below the 40th percentile at week 4, the protocol is likely not working and something needs to change. See the sermorelin protocol guide for specific monitoring intervals.
Measure IGF-1 at baseline, again at week 4, then every 8 to 12 weeks while on protocol. If the 4-week value has not moved at all, one of three things is happening: the peptide is under-dosed, the pharmacy's product is subpotent, or your somatotroph response is blunted. That data point tells you which problem to investigate. Without the baseline, you have no way to know which one it is.
Your genes can narrow the list before you walk in the door
6. Upload your genetic data before the appointment, not after
The average person walks into their first peptide therapy appointment and lets the clinic decide what to prescribe. They describe their goals (recovery, body composition, sleep, skin) and receive the clinic's standard protocol, adjusted only by age and sex. That protocol is the same for everyone.
A smaller group of patients arrives with their genetic data already analyzed. They know whether they are a slow CYP3A4 metabolizer, which matters for every co-medication in their protocol. They know whether their IGF-1 pathway variants predict a strong or modest response to GH peptides. They know whether their inflammation genetics point toward healing peptides or metabolic peptides as the higher-leverage choice for their specific biology. They arrive with a shortlist of 3 to 5 peptides that match their biology and direct the clinical conversation from there instead of accepting a generic starting point.
The Korean Society for Laboratory Medicine's 2024 updated clinical pharmacogenomic guidelines, published in Annals of Laboratory Medicine (Rim, Kim, Kim et al., 2024), found that genotype-guided prescribing reduced clinically relevant adverse drug reactions by approximately 30 percent compared to standard prescribing. That is not a peptide-specific finding. But the underlying principle, matching compounds to your metabolic and receptor genetics before prescribing, applies directly to peptide selection.
The DNA-first peptide decision framework explains how to use your existing 23andMe or AncestryDNA raw data file to build that shortlist. If you have already tested with any major provider, your data is sitting in your account. Upload it here and a report identifies your top genetic peptide matches before anyone tries to sell you a protocol.
What your CYP panel tells your clinic (and what it does not)
Most peptides (BPC-157, TB-500, GHK-Cu, KPV) are not metabolized through CYP enzymes at all. They are cleared renally or broken down by hepatic peptidases the same way food protein is. Your CYP3A4 variant does not directly affect whether these peptides work.
Where CYP genetics matter is in your co-medications. If your protocol includes testosterone, DHEA, rapamycin, or any statin alongside your peptides, and you carry the CYP3A4*22 slow-metabolizer variant (about 5 percent of Europeans), those compounds can accumulate to 150 to 170 percent of intended blood levels at a standard dose. The CYP3A4 slow metabolizer guide covers which co-medications require dose adjustment and which do not. Bring this information to your first appointment if you are currently on any of those compounds.
How to tell a legitimate peptide clinic from a bad one before you walk in
| Question to ask | Legitimate answer | Red flag answer |
|---|---|---|
| What labs do I need first? | Specific named list: CMP, CBC, IGF-1, hormone panel | "We do not require labs" or "get them after you start" |
| Which pharmacy do you use? | Named 503B facility, offers to share COA | Evasion, "proprietary", or a vague "licensed pharmacy" |
| Is this peptide currently legal to compound? | Cites specific FDA document and current list status | Reassurance without naming any specific document |
| When do I recheck my labs? | Specific schedule (week 4, then every 8 to 12 weeks) | "Whenever you feel you should" or no defined answer |
| What stops the protocol? | Defined thresholds (ALT over 5x upper limit, IGF-1 above 95th percentile) | No defined stop criteria mentioned at all |
7. Ask these 5 questions on the phone before you book anything
Call the clinic before you book your intake appointment. Five minutes screens out most of the bad options before you spend money on a consultation. Ask these questions in order:
- What labs do you require before prescribing? A specific named list is the only acceptable answer. Any answer that makes labs optional ends the call.
- Which 503B outsourcing facility do you source from? If they cannot name one immediately, their supply chain is unverified.
- Can I see the certificate of analysis before my first prescription is filled? A good clinic says yes without hesitation.
- Are all the peptides you prescribe currently on the FDA's approved bulk substances list? This weeds out clinics prescribing legally blocked compounds.
- What is your monitoring schedule after I start? No defined re-check interval means no supervised care.
Clear, specific answers to all five: book the appointment. Evasion on any one: that is diagnostic information about how the clinic operates. The 10 minutes this call takes is the single highest-leverage action you can take before your first peptide therapy appointment.
Verdict: A good first peptide therapy appointment starts two weeks before you walk in the door. Order your labs, verify your pharmacy, check the legal status of the peptide you are considering, know your IGF-1 if you are targeting GH protocols, and upload your genetic data to know which peptides match your biology before anyone tries to sell you a plan. The clinics worth going to will welcome all of this. The ones that push back are telling you something important. If you already have a 23andMe or AncestryDNA file, upload your data now to get your genetic peptide matches before your appointment. If you have not tested yet, an at-home saliva kit turns around results before most clinic consultation waiting lists clear.
Your DNA shapes how you respond to the peptides discussed above.
A personalized report scores 25+ peptides against your unique genetic profile — including the ones covered in this article.
Frequently asked questions
What labs do I need before starting peptide therapy?
The standard pre-treatment panel includes a Comprehensive Metabolic Panel (CMP), Complete Blood Count (CBC), fasting lipid panel, HbA1c, fasting insulin, and a hormone panel with morning cortisol and sex hormones. Add IGF-1 if you are starting GH-releasing peptides like sermorelin or CJC-1295. Add calcitonin and TSH if you are starting a GLP-1 peptide. For healing peptides like BPC-157 and TB-500, add high-sensitivity CRP and ESR as inflammatory baselines. A walk-in lab service can run the full panel for $100 to $250 without a doctor's order.
How do I know if a peptide therapy clinic is legitimate?
A legitimate clinic requires specific pre-treatment lab work before prescribing, names a specific FDA-registered 503B outsourcing facility as its compounding source, provides a certificate of analysis on request, and has a defined monitoring schedule with lab re-checks after starting. Calling the clinic before booking and asking those four questions directly is the most reliable screen. Any evasion on the pharmacy question or labs question is a red flag.
Do I need to fast before peptide therapy blood work?
Yes for most of the important markers. Fasting for 8 to 12 hours is required for accurate glucose, fasting insulin, triglycerides, and HOMA-IR. IGF-1 is most accurately drawn in the morning fasted, though it is less time-sensitive than glucose markers. Liver enzymes and CBC do not strictly require fasting but are usually drawn at the same time. Plan the draw for early morning after a full overnight fast.
Are peptide therapy clinics covered by insurance?
Almost never. Most peptides used in these protocols are not FDA-approved drugs, so standard health insurance does not cover compounding costs, consultations framed around off-label compounds, or monitoring labs ordered as part of an optimization protocol. A realistic first-year budget for a supervised single-peptide protocol with monitoring labs is $1,500 to $3,000 depending on the peptide and clinic location. Some labs may be reimbursable if ordered with a diagnosis code a physician can justify.
What is the difference between a 503A and 503B compounding pharmacy?
A 503A pharmacy compounds patient-specific prescriptions for named individual patients under state pharmacy board oversight. A 503B outsourcing facility is FDA-registered, operates under federal cGMP manufacturing standards, and can produce batches for distribution to clinics. For peptides, 503B provides the strongest quality control guarantees because it involves FDA inspections and pharmaceutical-grade documentation. Both are legitimate options. 503B is the higher standard.
How long before peptide therapy starts working?
It depends entirely on the peptide and the target outcome. GH-releasing peptides like sermorelin produce subtle energy and sleep improvements within 2 to 4 weeks, with body composition changes taking 3 to 6 months of consistent use. BPC-157 shows effects in animal models within 2 to 4 weeks, but human timelines remain undocumented in published research. Tracking your baseline labs gives you the only objective data point for measuring whether anything is happening at all.
Can I use my 23andMe data to prepare for a peptide therapy appointment?
Yes, and it is one of the highest-leverage steps you can take before your first visit. Your raw data file contains variant calls for CYP enzyme genes (relevant if you take other medications alongside peptides), IGF-1 pathway SNPs that predict GH peptide response strength, and inflammation genetics that predict whether healing or metabolic peptides are the higher-leverage intervention for your biology. Arriving with a genetic peptide report lets you direct the clinical conversation toward the compounds most likely to work for your specific biology instead of accepting a protocol designed for no one in particular.
This article is for informational and educational purposes only. It is not medical advice and does not diagnose, treat, cure, or prevent any disease. Consult a qualified healthcare professional before starting any peptide protocol. Individual results vary.